title: [Platelet activation and inflammation markers in patients with coronary heart disease and depression].
abstract: OBJECTIVE
  To study morphological features and functional activity of platelets, their relations with the level of inflammation markers in coronary heart disease (CHD) patients with depression.
  
  
  METHODS
  The study group consisted of 33 CHD patients with stable effort angina (NY-HA FC I-III), 14 had depression, 19 were free of depression. Sixteen healthy volunteers comprised the control group. Platelet aggregation was registered by a mean size of aggregates and turbidometrically. Platelets shape, leukocytic-thrombocytic and erythrocytic-thrombocytic aggregates (LTA, ETA) in the whole blood were studied electron-microscopically. The levels of IL-2, IL-6, TNF-alpha, sVCAM, hsCRP were measured in the blood, serotonin--in platelets.
  
  
  RESULTS
  Spontaneous aggregation enhanced in 52.6% CHD patients (p < 0.05). The blood contained reticular platelets, high number of prothrombocytes (p < 0.05), mean volume of thrombocytes was greater (p < 0.05). This reflected changes in megakaryocytopoiesis. Some of the patients had LTA and ETA. Out of inflammation markers, only IL-6 and sVCAM were elevated (p < 0.01), hsCRP concentration rose, but not above normal range. Serotonin in platelets was the same in the patients and controls. Depression aggravated the disorders and elevated other indices. Spontaneous aggregation was high in 71.4% of depressive CHD patients. The count of reticular platelets, prothrombocytes, mean volume platelets were also elevated. LTA and ETA were high in all the depressive patients. Elevated were also concentrations of IL-6, sVCAM, IL-2, hsCRP. Serotonin in platelets was low (p < 0.05).
  
  
  CONCLUSIONS
  Depression stimulates functional activity of platelets, is a factor of risk of intravascular inflammation and contributes to development of thrombotic complications in CHD patients.
authors.forename: L I
authors.initials: LI
authors.lastname: Buriachkovskaia
authors.forename: E O
authors.initials: EO
authors.lastname: Poliakova
authors.forename: A V
authors.initials: AV
authors.lastname: Zorin
authors.forename: I A
authors.initials: IA
authors.lastname: Uchitel'
authors.forename: N L
authors.initials: NL
authors.lastname: Dovlatova
authors.forename: V P
authors.initials: VP
authors.lastname: Masenko
authors.forename: A B
authors.initials: AB
authors.lastname: Sumarokov
authors.forename: E B
authors.initials: EB
authors.lastname: Kadushina
authors.forename: T A
authors.initials: TA
authors.lastname: Kuzentsova
authors.forename: T E
authors.initials: TE
authors.lastname: Pogorelova
authors.forename: E I
authors.initials: EI
authors.lastname: Chazov
mesh_terms: D000368:Aged; D003327:Coronary Disease / Q000453:epidemiology / Q000276:immunology*; D003863:Depression / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology*; D015850:Interleukin-6 / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism; D019010:Vascular Cell Adhesion Molecule-1 / Q000276:immunology*
chemical_list: D007376:Interleukin-2; D015850:Interleukin-6; D019010:Vascular Cell Adhesion Molecule-1; D012701:Serotonin